244 related articles for article (PubMed ID: 19713999)
1. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development.
Rao DD; Senzer N; Cleary MA; Nemunaitis J
Cancer Gene Ther; 2009 Nov; 16(11):807-9. PubMed ID: 19713999
[TBL] [Abstract][Full Text] [Related]
2. siRNA vs. shRNA: similarities and differences.
Rao DD; Vorhies JS; Senzer N; Nemunaitis J
Adv Drug Deliv Rev; 2009 Jul; 61(9):746-59. PubMed ID: 19389436
[TBL] [Abstract][Full Text] [Related]
3. RNAi in functional genomics.
Scherr M; Eder M
Curr Opin Mol Ther; 2004 Apr; 6(2):129-35. PubMed ID: 15195923
[TBL] [Abstract][Full Text] [Related]
4. Identifying siRNA-induced off-targets by microarray analysis.
Anderson E; Boese Q; Khvorova A; Karpilow J
Methods Mol Biol; 2008; 442():45-63. PubMed ID: 18369777
[TBL] [Abstract][Full Text] [Related]
5. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
Takahashi Y; Nishikawa M; Takakura Y
Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
[TBL] [Abstract][Full Text] [Related]
6. Primer extension-based method for the generation of a siRNA/miRNA expression vector.
Gou D; Zhang H; Baviskar PS; Liu L
Physiol Genomics; 2007 Nov; 31(3):554-62. PubMed ID: 17804605
[TBL] [Abstract][Full Text] [Related]
7. Evidence for targeting common siRNA hotspots and GC preference by plant Dicer-like proteins.
Ho T; Wang H; Pallett D; Dalmay T
FEBS Lett; 2007 Jul; 581(17):3267-72. PubMed ID: 17597620
[TBL] [Abstract][Full Text] [Related]
8. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
Reischl D; Zimmer A
Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
[TBL] [Abstract][Full Text] [Related]
9. Potential use of RNA interference in cancer therapy.
Phalon C; Rao DD; Nemunaitis J
Expert Rev Mol Med; 2010 Aug; 12():e26. PubMed ID: 20716384
[TBL] [Abstract][Full Text] [Related]
10. RNA interference for the treatment of cancer.
Putral LN; Gu W; McMillan NA
Drug News Perspect; 2006; 19(6):317-24. PubMed ID: 16971967
[TBL] [Abstract][Full Text] [Related]
11. [RNA interference and molecular pathology of selected diseases].
Lochmanová J; Bartos M
Cas Lek Cesk; 2008; 147(12):607-15. PubMed ID: 19235485
[TBL] [Abstract][Full Text] [Related]
12. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs.
Yang M; Mattes J
Pharmacol Ther; 2008 Jan; 117(1):94-104. PubMed ID: 17928059
[TBL] [Abstract][Full Text] [Related]
13. Small RNAs: delivering the future.
Blow N
Nature; 2007 Dec; 450(7172):1117-20. PubMed ID: 18075597
[No Abstract] [Full Text] [Related]
14. Review article: RNA interference--potential therapeutic applications for the gastroenterologist.
Pellish RS; Nasir A; Ramratnam B; Moss SF
Aliment Pharmacol Ther; 2008 May; 27(9):715-23. PubMed ID: 18248657
[TBL] [Abstract][Full Text] [Related]
15. The RNAi revolution.
Novina CD; Sharp PA
Nature; 2004 Jul; 430(6996):161-4. PubMed ID: 15241403
[No Abstract] [Full Text] [Related]
16. Strategies for short hairpin RNA delivery in cancer gene therapy.
Wang SL; Yao HH; Qin ZH
Expert Opin Biol Ther; 2009 Nov; 9(11):1357-68. PubMed ID: 19761417
[TBL] [Abstract][Full Text] [Related]
17. Design and validation of siRNAs and shRNAs.
Tilesi F; Fradiani P; Socci V; Willems D; Ascenzioni F
Curr Opin Mol Ther; 2009 Apr; 11(2):156-64. PubMed ID: 19330721
[TBL] [Abstract][Full Text] [Related]
18. Chemical modifications rescue off-target effects of RNAi.
Snøve O; Rossi JJ
ACS Chem Biol; 2006 Jun; 1(5):274-6. PubMed ID: 17163754
[TBL] [Abstract][Full Text] [Related]
19. Targeting neurological disease with RNAi.
Lingor P; Bähr M
Mol Biosyst; 2007 Nov; 3(11):773-80. PubMed ID: 17940660
[TBL] [Abstract][Full Text] [Related]
20. Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies.
Vorhies JS; Nemunaitis J
Expert Rev Anticancer Ther; 2007 Mar; 7(3):373-82. PubMed ID: 17338656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
